Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1001

Enrollment

INDUSTRY

Sponsor class

Conditions

Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions

BIOLOGICAL: 30 µg/strain of Quadrivalent VLP Vaccine
BIOLOGICAL: 60 µg/strain of Quadrivalent VLP Vaccine
BIOLOGICAL: FluLaval® Tetra (15 µg/strain)
BIOLOGICAL: Fluzone® High-Dose (60 µg/strain)

Sponsor

Medicago